Clinical collaboration Resminostat is in pivotal trials for CTCL in Europe and Japan, indicating a need for international clinical and regulatory support, partner access, or expanded collaboration opportunities with Japanese counterparts.

Expansion potential The RESMAIN CTCL maintenance study spans over 50 centers in 11 European countries and Japan, signaling a broad clinical network and potential for additional investigator-initiated studies, patient recruitment services, and data partnerships.

HDAC portfolio Resminostat covers multiple histone deacetylase classes and demonstrates tumor inhibition and immune activation, suggesting opportunities for combination therapy research, companion diagnostics, and strategic alliances with other oncology developers.

Financial runway With substantial funding and a listed Prime Standard profile, 4SC presents a partner-ready profile for co-development, milestone-driven financing, or equity-backed research collaborations to accelerate late-stage programs.

Digital reach Active web and social presence alongside modern tech stack indicates readiness for digital partnership outreach, trial recruitment campaigns, and sponsored content to engage researchers and potential global collaborators.